Natera at the 2026 ASCO Annual Meeting
Shaping the future of precision oncology
Come visit us at booth 14046 the 2026 American Society of Clinical Oncology (ASCO) Congress on May 30-June 2, 2026
Built to support clinical decision-making, from early recurrence risk assessment to surveillance monitoring to metastatic disease management, Natera helps bring clarity to complex treatment decisions.
Stop by our booth to learn more about our 35+ abstracts to be presented, spanning breast, genitourinary, lung, lymphoma, melanoma and colorectal cancer, and augmented by our expansive suite of oncology products. Discover why Signatera™ Residual Disease test is the most widely validated and extensively published MRD assay with broad patient access to help answer important clinical questions along the entire continuum of care.
Natera is presenting important new data demonstrating the clinical utility and performance of Signatera™ Residual Disease (MRD) test for patients with multiple cancer types.
Saturday May 30
ORAL – CRC
Title: Benefit of adjuvant chemotherapy in resected Stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study
Presenter: Mitsuru Yokota
Presentation Details: Clinical Science symposium – ctDNA in clinical practice: From detection to clinical decision making
Abstract #: 102
Date / Time: May 30, 2026, 8-9AM CDT
Title: A large-scale, multi-target deep learning model for virtual genomic and molecular risk profiling in colorectal cancer
Presenter: Erik N Bergstrom
Presentation Details: Poster session – Gastrointestinal Cancer—Colorectal and Anal
Abstract #: 3526 / Poster Board: 280
Date / Time: May 30, 2026, 9:00 AM – 12:00 PM CDT
Poster – CRC
Title: Impact of Postsurgical circulating tumor DNA (ctDNA) Dynamics on Eligibility of Colorectal Cancer (CRC) patients for Randomized ALTAIR Trial: Implications for Treat-on-Molecular-Recurrence (TOMR) Trials
Presenter: Hideaki Bando
Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal
Abstract #: 3628 / Poster Board: 395
Date / Time: May 30, 2026, 9:00 AM – 12:00 PM CDT
Poster – Esophageal
Title: Prognostic Value of Perioperative ctDNA Monitoring in Patients with Esophageal Squamous Cell Carcinoma (ESCC) Undergoing Neoadjuvant Chemotherapy (NAC) and Surgery
Presenter: Akinori Watanabe
Presentation Details: Akinori Watanabe
Abstract #: 4094 / Poster Board: 77
Date / Time: May 30, 2026, 9:00 AM – 12:00 PM CDT
Poster – CRC
Title: Comparison of Longitudinal Circulating tumor DNA (ctDNA) and carcinoembryonic antigen (CEA) for Post-operative Risk Stratification in Colorectal Cancer (CRC)
Presenter: Eiji Oki
Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal
Abstract #: 3637 / Poster Board: 404
Date / Time: May 30, 2026, 9:00 AM – 12:00 PM CDT
Poster – Gastric Cancer
Title: Prevalence of CDH1 germline variants in gastric cancer patients with exome-inferred ancestry
Presenter: Skylar Nahi
Presentation Details: Session: GI cancer (Gastroeso, Pancreatic, and Hep) Board 56; 5/30, 9am–12pm
Abstract #: 4073 / Poster Board: 56
Date / Time: May 30, 2026, 9:00 AM – 12:00 PM CDT
Title: Consensus molecular subtypes, mutational features, and circulating tumor DNA dynamics in colorectal cancer: a real-world clinico-genomic analysis
Presenter: Imad Shureiqi
Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal
Abstract #: 3652 / Poster Board: 419
Date / Time: May 30, 2026, 9:00 AM – 12:00 PM CDT
Poster – Colon Cancer
Title: Correlation of presurgical circulating tumor DNA (ctDNA) Levels with Pathologic (p)Stage and Lymph Node (LN) Burden in Localized Colon Cancer
Presenter: Masahito Kotaka
Abstract #: 3048 / Poster Board: 185
Date / Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Poster – Gastric Cancer
Title: Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: exploratory analyses from the phase 2 EPOC 2003 study
Presenter: Kawazoe
Presentation Details: Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #: 3129 / Poster Board: 266
Date / Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Poster – Melanoma
Title: Early ctDNA dynamics assessed by a personalized whole-genome sequencing-based assay predicts outcomes with immune checkpoint blockade in advanced melanoma
Presenter: Mora Guardamagna (INLIM)
Presentation Details: Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #: 3053 / Poster Board: 190
Date / Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Title: Performance of a tissue-free, molecular residual disease assay in colorectal, breast, and lung cancers from circulating tumor DNA.
Presenter: Princy Parsana
Presentation Details: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #: 3042 / Poster Board: 179
Date / Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Title: Ultrasensitive tumor-informed ctDNA MRD detection identifies metastatic relapse and predicts recurrence-free survival following resection of early-stage NSCLC
Presenter: Fernando Pikabea Diaz
Presentation Details: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #: 3060 / Poster Board: 197
Date / Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Sunday May 31
ORAL – CRC
Title: Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics
Presenter: Eiji Oki
Presentation Details: Oral Abstract Session – Gastrointestinal Cancer—Colorectal and Anal
Abstract #: 3501
Date / Time: May 31, 2026, 8:00 AM – 11:00 AM CDT
Poster – Advanced Urothelial Carcinoma
Title: Longitudinal Tumor-Informed ctDNA Monitoring and Clinical Outcomes in Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab
Presenter: Adanma Ayanambakkam
Presentation Details: Poster Session – Genitourinary Cancer—Kidney and Bladder
Abstract #: 4569 / Poster Board: 48
Date / Time: May 31, 2026, 9:00 AM – 12:00 PM CDT
Poster – MIBC
Title: Patient (pt)-reported outcomes (PROs) from IMvigor011: A Phase 3 study of circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) vs placebo (pbo) in muscle-invasive bladder cancer (MIBC)
Presenter: Joaquim Bellmunt
Presentation Details: Poster Session – Genitourinary Cancer—Kidney and Bladder
Abstract #: TBD / Poster Board: 106
Date / Time: May 31, 2026, 9:00 AM – 12:00 PM CDT
Poster – Melanoma
Title: Longitudinal monitoring for post-surgical molecular residual disease in patients with stage I–IIIB melanoma using a whole-genome sequencing–based ctDNA assay
Presenter: Karam Khaddour
Presentation Details: Poster Session – Melanoma/Skin Cancers
Abstract #: 9577 / Poster Board: 293
Date / Time: May 31, 2026, 9:00 AM – 12:00 PM CDT
Poster – Advanced Urothelial Carcinoma
Title: Circulating Tumor DNA (ctDNA) Dynamics As Early Biomarkers of Response to Enfortumab Vedotin plus Pembrolizumab (EVP) in Advanced Urothelial Carcinoma (aUC)
Presenter: Mohammad Jad Moussa
Presentation Details: Poster Session – MIBC
Abstract #: 4582 / Poster Board: 61
Date / Time: May 31, 2026, 9:00 AM – 12:00 PM CDT
Poster – NSCLC
Title: Circulating tumor DNA dynamics following molecularly targeted therapy for non-small cell lung cancer
Presenter: Justin Jee
Presentation Details: Poster Session – Lung Cancer—Non-Small Cell Metastatic
Abstract #: 8652 / Poster Board: 442
Date / Time: May 31, 2026, 9:00 AM – 12:00 PM CDT
Monday June 1
Poster – Pancancer
Title: Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: a real-world meta-analysis
Presenter: Scott Kopetz
Presentation Details: Poster Session – Quality Care/Health Services Research
Abstract #: 11177 / Poster Board: 160
Date / Time: June 1, 2026, 9:00 AM – 12:00 PM CDT
Poster – Ovarian Cancer
Title: Post-Treatment ctDNA Monitoring Using a Tumor-Informed Whole-Genome Sequencing-Based Assay in Homologous Recombination–Proficient Ovarian Cancer
Presenter: Sophie Blakey-Cheung
Presentation Details: Poster Session – Gynecologic Cancer
Abstract #: 5592 / Poster Board: 258
Date / Time: June 1, 2026, 9:00 AM – 12:00 PM CDT
Poster Session – Soft Tissue Sarcoma
Title: Integrating Personalized ctDNA into Clinical Surveillance of Soft Tissue Sarcoma: Performance, Timing, and Histologic Insights.
Presenter: Amrit Paude
Presentation Details: Poster Session – Sarcoma
Abstract #: 11581
Date / Time: June 1, 2026, 1:30 PM – 4:30 PM CDT
CRC – Details TBD
Title: A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Presenter: Neil Segal
Presentation Details:
Abstract #:
Date / Time:
Poster – Uterine Cancer
Title: Whole-Genome Sequencing-Based ctDNA Testing for Post-Surgical Monitoring and Early Detection of Recurrence or Progression in Uterine Cancer
Presenter: Abigail Barger
Presentation Details:
Abstract #: TBD
Date / Time:
Poster – EMPOWER (GI and Gyn)
Title: Prevalence of microsatellite stable Lynch Syndrome supports universal germline testing: a pan-cancer analysis of 246,694 patients
Presenter: Casey Cosgrove
Presentation Details: Poster Session – Prevention, Risk Reduction, and Genetics Poster
Abstract #: 10613 / Poster Board: 574
Date / Time:
Title: Assessment of measurable residual disease (MRD) by circulating tumor (ct)DNA in patients (pts) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucel (liso-cel) in TRANSCEND FL
Presenter: Ariel Avilion
Presentation Details: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract #: Poster Board: 523
Date / Time: June 1, 2026, 9:00 AM – 12:00 PM CDT
Title: ASPRIA: A Single Arm Phase 2 Trial of Atezolizumab with Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer
Presenter: Payal D. Shah
Presentation Details: Poster Session – Breast Cancer—Local/Regional/Adjuvant
Abstract #: TPS644
Date / Time: June 1, 2026, 1:30 PM – 4:30 PM CDT
Title: PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC with Residual Disease
Presenter: Yara Abou
Presentation Details: Poster Session – Breast Cancer—Local/Regional/Adjuvant
Abstract #: TPS647 / Poster Board: 129b
Date / Time: June 1, 2026, 1:30 PM – 4:30 PM CDT
Title: SIGNAL-ER-101: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Presenter: Marla Lipsyc-Sharf
Presentation Details: Poster Session – Breast Cancer—Local/Regional/Adjuvant
Abstract #: 2594 / Poster Board: 384
Date / Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Tuesday June 2
Oral
Title: Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI)
Presenter: Hannah R. Robinson
Presentation Details: Gastrointestinal Cancer—Colorectal and Ana
Abstract #: 3516
Date / Time: June 2, 2026, 8:00 AM – 9:30 AM CDT
Poster – Uterine Cancer
Title: Whole-Genome Sequencing-Based ctDNA Testing for Post-Surgical Monitoring and Early Detection of Recurrence or Progression in Uterine Cancer
Presenter: Abigail Barger
Presentation Details:
Abstract #: TBD
Date / Time:
Poster – EMPOWER (GI and Gyn)
Title: Prevalence of microsatellite stable Lynch Syndrome supports universal germline testing: a pan-cancer analysis of 246,694 patients
Presenter: Casey Cosgrove
Presentation Details: Poster Session – Prevention, Risk Reduction, and Genetics Poster
Abstract #: 10613 / Poster Board: 574
Date / Time:
Session Details TBD
Title: Tumor-Informed ctDNA as a Biomarker of Outcomes Following Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
Presenter: Marina Andreadis
Presentation Details:
Abstract #:
Date / Time:
Session Details TBD – Melanoma
Title: Optimal timing of circulating tumor DNA (ctDNA) dynamics to prognosticate immune checkpoint inhibitors (ICI) efficacy in patients with advanced stage melanoma
Presenter: Vincent Ma
Presentation Details:
Abstract #:
Date / Time:
Title: Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma.
Presenter: Vincent Ma
Presentation Details:
Abstract #:
Date / Time:
Poster – CSCC
Title: Circulating tumor DNA ctDNA as a biomarker for pathological response and clinical outcomes in patients with cutaneous squamous cell carcinoma CSCC receiving neoadjuvant anti-PD-1 therapy.
Presenter: Karam Khaddour
Presentation Details: Session details TBD
Abstract #:
Date / Time:
Poster Presentation TBD
Title: ctDNA clearance durability and progression-free survival in unresectable or metastatic cutaneous malignancies
Presenter: Sekwon Jang
Presentation Details:
Experience Annotation
The longitudinal context you’ve been missing.
View molecular results layered with diagnosis, surgery and therapy response.
See Annotation in practice.
To learn more about this and other important data as well as how Signatera™ may be used to help answer key clinical questions within your practice
Patient Testimonial
“… if I wouldn’t have had this Signatera™ test, it would have progressed to the point where a liver ablation was not an option. My liver surgeon [said] you’re a year ahead of the game because of the test.”
From diagnosis to survivorship, Natera supports patients across the continuum of care
